RAPACURONIUM BROMIDE - Generic Drug Details

What are the generic drug sources for rapacuronium bromide and what is the scope of patent protection?

Rapacuronium bromide is the generic ingredient in one branded drug marketed by Organon Usa Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for RAPACURONIUM BROMIDE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	29
DailyMed Link:	RAPACURONIUM BROMIDE at DailyMed

US Patents and Regulatory Information for RAPACURONIUM BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	RAPLON	rapacuronium bromide	INJECTABLE;INJECTION	020984-002	Aug 18, 1999		DISCN	No	No
Organon Usa Inc	RAPLON	rapacuronium bromide	INJECTABLE;INJECTION	020984-001	Aug 18, 1999		DISCN	No	No

Expired US Patents for RAPACURONIUM BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	RAPLON	rapacuronium bromide	INJECTABLE;INJECTION	020984-001	Aug 18, 1999
Organon Usa Inc	RAPLON	rapacuronium bromide	INJECTABLE;INJECTION	020984-002	Aug 18, 1999

Rapacuronium Bromide Market Dynamics and Financial Trajectory

Last updated: September 8, 2026

Rapacuronium bromide was a short-lived neuromuscular-blocking drug marketed by Organon under the brand name Raplon. The FDA approved it in 1999 for use as an adjunct to general anesthesia and for rapid tracheal intubation. Its commercial opportunity ended in 2001 after reports of severe and fatal bronchospasm. Organon voluntarily withdrew Raplon from the U.S. market, and rapacuronium bromide has no meaningful current sales, active commercial market, or established generic-entry opportunity. [1][2]

What was rapacuronium bromide used for?

Rapacuronium bromide was an aminosteroid neuromuscular blocker developed for rapid muscle relaxation during anesthesia and tracheal intubation. Its development code was ORG 9487. Organon developed and marketed the product through its U.S. operations.

The drug was intended to compete in a market that included:

• Succinylcholine, widely used for rapid-sequence intubation
• Rocuronium bromide, marketed as Zemuron
• Vecuronium bromide
• Atracurium besylate
• Cisatracurium besylate, marketed as Nimbex

Rapacuronium was positioned around rapid onset and relatively short duration. It was intended to provide an alternative to succinylcholine, particularly where clinicians wanted to avoid succinylcholine-associated adverse effects such as hyperkalemia, malignant hyperthermia risk, or prolonged paralysis in susceptible patients.

The commercial proposition depended on a favorable safety tradeoff. Rapacuronium did not achieve that requirement.

When was rapacuronium bromide approved and withdrawn?

Event	Date	Commercial significance
FDA approval of Raplon	August 1999	Initiated U.S. commercial launch
Postmarketing bronchospasm reports	1999-2001	Created material safety concerns
FDA safety communications and regulatory scrutiny	Early 2001	Reduced physician confidence and use
Organon voluntary withdrawal	March 2001	Ended U.S. commercial sales
Post-withdrawal market	2001 onward	No established commercial market

The FDA approved rapacuronium bromide injection in August 1999. Within approximately 18 months, serious respiratory events had become the dominant commercial and regulatory issue. The FDA reported severe bronchospasm, including cases requiring mechanical ventilation and cases associated with death. [1]

Organon withdrew Raplon voluntarily in March 2001. The withdrawal was driven by the risk of severe bronchospasm rather than by weak efficacy, manufacturing failure, or a conventional patent-expiration event. [2]

Why did rapacuronium bromide fail commercially?

The principal failure was an unfavorable safety profile in the exact clinical setting where the drug was expected to gain adoption: rapid airway management.

Bronchospasm can complicate ventilation and intubation. A neuromuscular blocker associated with serious bronchospasm creates a direct clinical risk during anesthesia, particularly in patients with pulmonary disease or airway hyperreactivity. Reports of severe and fatal cases materially changed the product’s risk-benefit assessment.

The commercial consequences were immediate:

1. Anesthesia providers had established alternatives.
2. Succinylcholine remained familiar and inexpensive.
3. Rocuronium provided a competing nondepolarizing option for rapid intubation.
4. The clinical benefit of rapacuronium was not sufficiently differentiated to offset the safety signal.
5. A short period after launch limited physician adoption and institutional formulary penetration.

Rapacuronium’s market position was therefore vulnerable even before withdrawal. The product entered a mature hospital market with entrenched alternatives, strong physician familiarity, and purchasing pressure from hospital pharmacy departments.

How did rapacuronium compare with rocuronium and succinylcholine?

Attribute	Rapacuronium	Rocuronium	Succinylcholine
Pharmacologic class	Nondepolarizing aminosteroid	Nondepolarizing aminosteroid	Depolarizing neuromuscular blocker
Intended use	Rapid intubation and anesthesia adjunct	Rapid intubation and anesthesia adjunct	Rapid-sequence intubation
Market status	Withdrawn	Commercially established	Commercially established
Main commercial issue	Severe bronchospasm	Dose-related duration and hypersensitivity concerns	Hyperkalemia, malignant hyperthermia, bradycardia and other risks
Competitive position	Failed	Stronger long-term substitute	Low-cost incumbent
Current commercial relevance	None	Active	Active

Rocuronium was the closest competitive benchmark. It also offered relatively rapid onset and was supported by established clinical use. Once rapacuronium developed a serious respiratory safety concern, hospitals had little economic or clinical reason to switch from rocuronium or succinylcholine.

The withdrawal also benefited subsequent alternatives, including improved use of rocuronium with sugammadex in markets where sugammadex became available. Sugammadex can rapidly reverse certain aminosteroid neuromuscular blockers, including rocuronium and vecuronium. That reversal option strengthened the long-term competitive position of rocuronium, although it was not available as a commercial rescue strategy for rapacuronium.

What was the financial trajectory of rapacuronium bromide?

Rapacuronium followed a launch-to-withdrawal trajectory rather than a conventional pharmaceutical lifecycle.

Financial phase	Approximate period	Assessment
Development	Before 1999	Investment in discovery, clinical development, regulatory review and manufacturing
Launch	1999	Initial hospital-market entry
Limited commercial uptake	1999-2000	Adoption constrained by safety concerns and established alternatives
Safety-driven contraction	2000-early 2001	Demand and formulary confidence deteriorated
Withdrawal	March 2001	Product revenue effectively ended
Post-withdrawal	2001-present	No meaningful commercial revenue

Organon did not establish a durable revenue stream from Raplon. Public company reporting from the period did not provide a widely reported, standalone Raplon revenue series comparable to major pharmaceutical products. The product was commercially immaterial relative to Organon’s broader portfolio, and its short market life prevented meaningful scale.

The financial loss extended beyond foregone product sales. Organon also faced sunk costs associated with:

• Clinical trials and regulatory submissions
• Manufacturing scale-up
• Hospital sales and medical education
• Distribution and inventory
• Postmarketing surveillance
• Regulatory and pharmacovigilance activity
• Product withdrawal and market remediation

The financial profile was therefore negative on a lifecycle basis even though the product had received regulatory approval. Approval did not translate into recovery of development and launch investment.

What market dynamics affected rapacuronium sales?

Hospital procurement favored established agents

Neuromuscular blockers are primarily institutional products. Hospital formulary decisions depend on clinical familiarity, supply reliability, acquisition cost, reversal protocols, and anesthesia department preference. A new agent must show a clear advantage to displace products already embedded in operating-room protocols.

Rapacuronium’s clinical differentiation was narrow. Rapid onset and short duration were useful, but comparable attributes were available from other drugs. The product did not establish a durable cost or outcomes advantage.

Safety information spread quickly through specialist channels

Anesthesia providers monitor adverse events closely because airway and respiratory complications have immediate clinical consequences. Reports of bronchospasm could rapidly affect use across hospital systems even before a formal market withdrawal.

Generic competition was not the main threat

Rapacuronium did not fail because generic substitution eroded price. The commercial collapse occurred before a mature generic market developed. Safety-driven discontinuation destroyed demand before patent expiration became the central commercial issue.

The product lacked a viable defensive niche

Rapacuronium might have retained a niche if it had offered a unique clinical benefit for a defined patient population. The bronchospasm signal narrowed rather than expanded its addressable population. Patients with airway disease represented a particularly sensitive group, while other patients could be treated with existing agents.

What was the FDA regulatory status of rapacuronium bromide?

The FDA-approved indication covered use as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal-muscle relaxation during surgery or mechanical ventilation. [1]

The product’s regulatory history shifted from approval to safety action and withdrawal:

• Initial approval: FDA-approved injectable neuromuscular blocker
• Safety evaluation: review of postmarketing bronchospasm and death reports
• Market action: manufacturer withdrawal
• Current status: not marketed in the United States

Rapacuronium does not have a current commercial FDA market position. It is not a viable candidate for routine U.S. hospital procurement, and no current branded-product growth forecast is applicable.

What patents protected rapacuronium bromide?

Rapacuronium was protected during development by chemical, formulation, manufacturing, and use-related intellectual property associated with Organon and its corporate predecessors. Publicly available sources do not support a reliable current patent-life analysis for the product without reconstructing the historical patent family and relevant patent-term adjustments.

The commercial importance of those patents was limited by the 2001 withdrawal. Any remaining patent term after withdrawal would not have restored market value because the product’s principal barrier was clinical safety rather than generic competition.

Were formulation patents commercially important?

Formulation and injectable-product claims could have protected the dosage form, concentration, stability, or manufacturing process. Those claims would have mattered during the launch period if Raplon had achieved sustained adoption.

After withdrawal, formulation patents had little practical value. An injectable neuromuscular blocker requires regulatory approval, hospital acceptance, manufacturing capability, and a credible safety profile. Patent protection alone could not create demand for a withdrawn product.

Did method-of-use patents protect a viable market?

Method-of-use claims directed to rapid tracheal intubation, surgical muscle relaxation, or controlled ventilation could have supported market exclusivity. The same clinical uses, however, were served by multiple competing neuromuscular blockers.

The withdrawal eliminated the commercial value of method-of-use exclusivity. No meaningful commercial opportunity remained for enforcing use claims against competing products.

Did rapacuronium face Paragraph IV challenges?

There is no commercially significant Paragraph IV litigation record associated with rapacuronium comparable to major products that remained on the market through generic entry.

The likely reason is economic. A Paragraph IV challenge is attractive when the branded product has substantial remaining sales and a generic applicant can capture a large market. Rapacuronium had already been withdrawn before a generic-entry contest could develop. The relevant competitive event was safety-driven market exit, not patent litigation.

A future generic launch would also face a basic commercial problem: there is no established current market to capture. A generic applicant would need to create demand for a drug whose original brand was withdrawn for serious safety reasons.

What is the Orange Book status of rapacuronium bromide?

Rapacuronium’s current Orange Book relevance is limited. The product is no longer an active marketed reference product, and it does not represent a meaningful source of current listed-drug exclusivity or generic-entry risk.

Historical Orange Book listings may have identified Raplon and associated patent or exclusivity information during the product’s active period. Those historical listings do not create present commercial protection. The key distinction is between historical listing status and current marketability.

Are there biosimilar risks for rapacuronium bromide?

No. Rapacuronium bromide is a small-molecule drug, not a biologic. The biosimilar pathway under the Public Health Service Act does not apply.

Any hypothetical follow-on product would proceed through an abbreviated or full small-molecule drug pathway, depending on the reference-product and regulatory circumstances. In practice, the larger barrier is the absence of a viable market and the product’s safety history.

Which companies are challenging rapacuronium?

No active company-led challenge is commercially material. There is no significant current generic or biosimilar campaign against rapacuronium.

The relevant competitive companies during its market period included manufacturers of rocuronium, succinylcholine, vecuronium, atracurium, and cisatracurium. Their products competed through established clinical use, hospital contracts, physician familiarity, and lower adoption risk rather than through direct patent litigation against Raplon.

What generic launch risks exist for rapacuronium?

A generic launch would face limited patent risk but high commercial and regulatory risk.

Risk category	Assessment
Patent blocking risk	Low practical significance after withdrawal
Orange Book risk	Limited current relevance
FDA approval risk	Material because of historical safety concerns
Hospital adoption risk	Very high
Physician acceptance risk	Very high
Revenue opportunity	Minimal
Manufacturing complexity	Moderate for sterile injectable production
Liability exposure	Potentially high

Sterile injectable manufacturing is itself a barrier. A supplier would need validated production, reliable quality systems, supply continuity, and a regulatory strategy appropriate for a withdrawn product. Those costs would be difficult to justify against an uncertain and limited market.

What licensing deals involved rapacuronium bromide?

The commercial program was associated with Organon, then part of Akzo Nobel’s pharmaceutical operations. No major post-withdrawal licensing transaction created a new commercial market for rapacuronium bromide.

The absence of a meaningful rescue licensing deal is consistent with the product’s risk profile. A licensee would have inherited the same safety history, regulatory burden, physician resistance, and limited revenue opportunity. The asset did not present a conventional lifecycle-management opportunity such as a new formulation, new indication, or geographic relaunch.

How strong was the rapacuronium patent estate?

The patent estate may have been technically adequate to support initial market exclusivity, but its commercial strength was weak.

Patent strength should be assessed across four dimensions:

1. Legal scope: chemical and use claims could have provided protection.
2. Remaining term: any surviving term lost value after withdrawal.
3. Enforcement value: low because no meaningful market remained.
4. Product differentiation: inadequate to offset safety concerns.

Rapacuronium illustrates the difference between patent exclusivity and economic exclusivity. A product can have valid patent rights and FDA approval yet fail to generate durable value if safety reduces demand.

What is the current commercial outlook for rapacuronium bromide?

The current outlook is effectively zero for branded sales, generic competition, licensing revenue, or meaningful market expansion.

The historical asset may retain analytical value for:

• Drug-safety case studies
• Anesthesia pharmacology research
• Regulatory-risk analysis
• Pharmaceutical portfolio postmortems
• Comparative evaluation of neuromuscular blockers

It does not represent an investable commercial drug opportunity under ordinary market conditions.

Key Takeaways

• Rapacuronium bromide was FDA-approved in 1999 and marketed as Raplon by Organon.
• The product was withdrawn in March 2001 after severe bronchospasm reports, including fatal cases.
• Its failure was safety-driven, not primarily patent-driven.
• Rapacuronium entered a mature market dominated by succinylcholine and competing nondepolarizing neuromuscular blockers.
• Product-level revenue was not publicly reported at a level that supports a reliable standalone financial series.
• The drug has no meaningful current U.S. market, active biosimilar risk, or commercially relevant Paragraph IV challenge.
• Patent and formulation rights lost practical value after withdrawal.
• A generic relaunch would face high regulatory, physician-acceptance, liability, and hospital-adoption risk.
• The product’s commercial trajectory was launch, limited uptake, safety contraction, and withdrawal.

FAQs

Is rapacuronium bromide still available in the United States?

No. Organon withdrew Raplon from the U.S. market in March 2001 after reports of serious bronchospasm.

What caused the withdrawal of Raplon?

The withdrawal followed postmarketing reports of severe bronchospasm, including cases requiring ventilation and cases associated with death.

Was rapacuronium more profitable than rocuronium?

No public evidence shows that Raplon achieved material profitability. Its short market life and safety-driven withdrawal prevented the scale reached by established alternatives such as rocuronium.

Can a generic manufacturer relaunch rapacuronium bromide?

A relaunch would be technically possible only through an appropriate FDA pathway, but the commercial case is weak because the drug lacks an established market and has a significant historical safety record.

Is rapacuronium bromide a controlled substance or biologic?

No. Rapacuronium bromide is a small-molecule neuromuscular blocker and is not a biologic or biosimilar product.

References

1. U.S. Food and Drug Administration. (2000). Raplon (rapacuronium bromide) injection: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2001, March 19). FDA public health notification: Rapacuronium bromide (Raplon) and severe bronchospasm. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Organon International. (2001). Annual report and corporate information. Akzo Nobel.